Ulcerative Colitis
Join us in a study to see how well a new treatment works when combined with an existing medication for adults with moderately to severely active ulcerative colitis (UC). This study will last about 118 weeks, including 104 weeks of treatment and up to 21 visits.
Study site: NeoClinical Research
- Ulcerative colitis (UC)
- About the Study
- This study aims to find out how well a new treatment works alongside an existing medication for adults with moderately to severely active ulcerative colitis (UC). If you join, you'll be contributing to important research that could help others with this condition. The study lasts about 118 weeks, with 104 weeks of treatment and up to 21 visits.
- What does the study involve?
- You'll receive treatments through pills and injections.
What to expect
- Placebo
- You may receive a placebo (a look-alike with no active medicine).
- Which treatment you get
- Chosen at random. Neither you nor the study team will know which treatment you get.
- Who can participate?
- We're looking for adults aged 18 and older with a diagnosis of moderately to severely active ulcerative colitis. You should have tried at least one UC medication without success. If you think you might qualify, apply to find out more!
Where is the study taking place?
Palmetto Medical Plaza
Study details
- Sponsor
- Eli Lilly and Company
- Phase
- Phase 2: testing whether it works, and its safety, in a larger group
- Dates
- November 2025 to March 2029 (expected)
- Size
- 252 participants across all sites
- Healthy volunteers
- Only people with the condition
Study details are from ClinicalTrials.gov. The rest of this page is written by the study site for patients and may summarize or reword the registry record, which is the official text. A study listed on ClinicalTrials.gov has not necessarily been reviewed or approved by the U.S. government.
About NeoClinical Research
NeoClinical Research is a leading, multi-therapeutic clinical research center based in South Florida that bridges the gap between leading pharmaceutical companies and diverse patient populations.